Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Synthetic Blood International and the Virginia Commonwealth University Tech Transfer have signed a license agreement allowing the company exclusive use of certain VCU discoveries.
Subscribe to our email newsletter
The Virginia Commonwealth University (VCU) discoveries relate to non-pulmonary oxygenation, enhanced oxygen transport to tissue, and gas-based wound and tissue therapeutics.
Chris Stern, chairman and CEO of Synthetic Blood, said: “These licenses will allow our company to develop novel products with Oxycyte in combination with hydrogen peroxide. We believe these can be developed to be used in cardiopulmonary indications and for revolutionary wound treatment indications and devices.”